Stocks Health care CTNM
NASDAQ · Health careContineum Therapeutics, Inc. (CTNM)
It posted a net loss of $57.6M. In fiscal 2025 capital spending exceeded operating cash flow by $55.5M. At June 30, 2026 it held $14.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 30, 2026.
What Contineum Therapeutics, Inc. does
Contineum Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CTNM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$60M | -$2.17 | -$55.5M |
| 2024 | $0 | -$42.3M | -$2.18 | -$33.4M |
| 2024 | $50M | $22.7M | $0.08 | $18.9M |
Latest SEC filings
What Contineum Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026
- July 30, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- July 17, 2026Passive stake changed SCHEDULE 13G/A
- July 13, 2026
- June 26, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
Questions about CTNM
What does Contineum Therapeutics, Inc. do?
Contineum Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CTNM.
Is Contineum Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $57.6M.
When did Contineum Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 30, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 14, 2026.
Similar companies
Follow CTNM
Get an email when Contineum Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CTNM: get an email when it filesWhere the numbers come from
Financial figures are the values Contineum Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.